ProMIS Neurosciences, based in Toronto, develops precision medicine for neurodegenerative diseases, focusing on antibody therapeutics targeting misfolded proteins. The company went public on April 3, 2017, and employs six full-time staff.
Neil Cashman bought 15,000 shares of PMN on 10 February at $0.97 per share, worth a total of $15K. They now own 16,617 PMN shares, or a 928% holding increase.
📡️ Health Care
Insider Trades
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
